Liquidia Adds Strategy To Its General Counsel's Job And Raises Salary To $625,000
The expanded role also brings a higher bonus target and a stock award whose share count uses a $500,000 value.
Liquidia, which develops and sells medicines for respiratory and vascular diseases, added chief strategy officer to general counsel Russell Schundler's role effective Monday. His salary increased to $625,000 a year, the company said in an 8-K filed Wednesday.
Strategy joins Schundler's legal role
Schundler keeps the general counsel title alongside his new strategy post. He has held the legal job since March 2021, and Liquidia's board approved the expanded appointment Thursday.
Liquidia increased his target annual bonus to 60% of base salary when the appointment took effect. The pay package combines that higher cash-pay opportunity with restricted stock units—an award that becomes vested over time under the company's employment requirements.
Stock award stretches into 2028
Liquidia used a $500,000 value to calculate the stock grant. The number of units equals that amount divided by the fair market value of a common share on Monday.
Schundler is scheduled to vest in 25% of the award on January 11, 2028. The rest vests in equal quarterly portions during the following three years. Each vesting date requires him to remain continuously employed by Liquidia.
YUTREPIA anchors the commercial business
Liquidia's treatments focus mainly on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its commercial business includes YUTREPIA, a dry-powder version of treprostinil that patients inhale through a dry-powder inhaler.
The FDA approved YUTREPIA in May 2025, and Liquidia launched it in June 2025. The company uses a U.S. field sales team to reach healthcare providers treating these patients.
Liquidia also earns revenue through an agreement to promote Sandoz's generic treprostinil injection, sharing profit from the product in the United States. Beyond its marketed treatments, the company researches, develops and manufactures new products. Its pipeline includes L606, a liposomal treprostinil candidate in clinical studies.
Sources
- 8-K Filing — Liquidia Corp (LQDA) — SEC EDGAR